Y. Kutlu Et Al. , "Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy," Medicine (United States) , vol.102, no.15, 2023
Kutlu, Y. Et Al. 2023. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy. Medicine (United States) , vol.102, no.15 .
Kutlu, Y., Aydin, S. G., Bilici, A., Oven, B. B., Ölmez, Ö. F., Açıkgöz, Ö., ... Hamdard, J.(2023). Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy. Medicine (United States) , vol.102, no.15.
Kutlu, Yasin Et Al. "Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy," Medicine (United States) , vol.102, no.15, 2023
Kutlu, Yasin Et Al. "Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy." Medicine (United States) , vol.102, no.15, 2023
Kutlu, Y. Et Al. (2023) . "Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy." Medicine (United States) , vol.102, no.15.
@article{article, author={Yasin KUTLU Et Al. }, title={Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy}, journal={Medicine (United States)}, year=2023}